Background The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
variants threatens progress toward control of the coronavirus disease 2019 (Covid-19) …

Background BCG vaccination provides incomplete protection against tuberculosis in infants.
A new vaccine, modified Vaccinia Ankara virus expressing antigen 85A (MVA85A), was …

Background Targeted preventive therapy for individuals at highest risk of incident tuberculosis
might impact the epidemic by interrupting transmission. We tested performance of a …

Background Results of an earlier analysis of a trial of the M72/AS01 E candidate vaccine
against Mycobacterium tuberculosis showed that in infected adults, the vaccine provided 54.0% …

Background A vaccine to interrupt the transmission of tuberculosis is needed. Methods We
conducted a randomized, double-blind, placebo-controlled, phase 2b trial of the M72/AS01 E …

Rationale: AERAS-402 is a novel tuberculosis vaccine designed to boost immunity primed by
bacillus Calmette-Guérin (BCG), the only licensed vaccine. Objectives: We investigated the …

Vaccines to protect against tuberculosis (TB) are urgently needed. We performed a case–control
analysis to identify immune correlates of TB disease risk in Bacille Calmette–Guerin (…

Modified vaccinia Ankara‐expressing Ag85A (MVA85A) is a new tuberculosis (TB) vaccine
aimed at enhancing immunity induced by BCG. We investigated the safety and …

Background A rapid, blood-based triage test that allows targeted investigation for tuberculosis
at the point of care could shorten the time to tuberculosis treatment and reduce mortality. …

Background. The efficacy of bacille Calmette-Guérin (BCG) may be enhanced by heterologous
vaccination strategies that boost the BCG-primed immune response. One leading booster …